| Component | Advantages | Disadvantages | Ref. |
---|---|---|---|---|
Natural ECM | Collagen | Recapitulation of In-Vivo Microenvironment, Relevant ECM Composition, Mimicking Breast Cancer Stiffness, Patient-Specific Drug Testing | Lack of Complexity, Stiffness Variability, ECM Heterogeneity, Matrix Remodeling Challenges | |
Elastin | Elasticity and Resilience, Biocompatibility and Biodegradability, No Immunogenicity | Limited Availability, Remodeling and Degradation, Influence on Tumor Growth | ||
Fibronectin | Scaffold for Tissue Development, Regulator of Cell Signal Transduction, Modulation of Cell Behavior, Potential Therapeutic Applications | Altered Cell Behavior, Potential Disease Implications, Limited Control of ECM Expression | ||
Laminin | Biomimetic Nature, Cell Behavior Regulation, Maintenance of Epithelial Cohesion | Overexpression in Breast Cancer, Complexity in Processing, Spatial Control and Heterogeneity | ||
Proteoglycans | Improved Biomimicry, Cellular Communication and Interaction, Matrix Turnover | ECM Complexity, Cost | ||
Synthetic ECM | Synthetic Hydrogels | Recreating Tumor Microenvironment, Cell-Cell and Cell-Matrix Interactions, Tissue Structure and Function, Alternative to Animal Models | Cost, Standardization and Reproducibility, Limited Availability of Synthetic Hydrogels, Learning Curve | |
Functionalized Peptides | Biomimicry, Cell-Cell and Cell-ECM Interactions, Tumor Microenvironment Modeling, Drug Screening Platforms | Cost, Lack of Standardization, Limited Peptide Repertoire | ||
Synthetic Polymer Scaffolds | Mimicking Tumor Microenvironment, Improved Cell-Cell and Cell-Matrix Interactions, Drug Screening and Therapeutic Efficacy Evaluation, Biocompatibility | Complexity of Fabrication, Limited Representation of In Vivo Conditions, Interference with Cellular Signaling | ||
Synthetic Peptide Epitopes | Mimicking Native Tumor Microenvironment, Regulating Biological Processes, Tunable 3D Models | Cost, Incomplete Replication of In-Vivo Environment, Lack of Long-term Stability |